Mealey's (May 21, 2020, 2:13 PM EDT) -- WASHINGTON, D.C. — A federal judge in the District of Columbia on May 19 dismissed without prejudice a relator’s False Claims Act (FCA) lawsuit claiming that Vanda Pharmaceuticals Inc.’s off-label promotion of an atypical antipsychotic and a drug used to treat 24-hour non-sleep disorder in blind patients resulted in the submission of fraudulent claims to Medicare and Medicaid (United States, ex rel. Richard Gardner v. Vanda Pharmaceuticals Inc., No. 17-cv-00464, D. D.C., 2020 U.S. Dist. LEXIS 87790)....